Mechanism of Action

Cidofovir (HPMPC) is an acyclic nucleoside phosphonate analogue of deoxycytidine monophosphate. Unlike nucleoside analogues that require an initial virus-encoded kinase step for activation, cidofovir already bears a phosphonate group that mimics the first phosphorylation product. Inside the host cell, cellular kinases convert cidofovir into its active diphosphate form, cidofovir diphosphate (CDV-PP).

CDV-PP competitively inhibits viral DNA polymerase by substituting for the natural substrate deoxycytidine triphosphate (dCTP). Once incorporated into the elongating viral DNA chain, the unusual phosphonate backbone slows or arrests further chain elongation, effectively acting as a DNA chain terminator. Because cidofovir activation depends on host cell kinases rather than viral kinases, it retains activity against viral strains with mutations in thymidine kinase or UL97 kinase genes that confer resistance to acyclovir or ganciclovir.

A key pharmacological feature is the formation of a cidofovir-choline phosphate metabolite that acts as an intracellular reservoir, prolonging the intracellular half-life of the active diphosphate and enabling infrequent dosing schedules in clinical and experimental settings.

Research Applications

Cidofovir has become an important research reagent in virology laboratories studying a wide range of double-stranded DNA viruses. Its primary experimental utility includes:

• Cytomegalovirus (CMV) Research: Cidofovir is widely used in cell culture and animal model systems to investigate CMV replication kinetics, resistance mechanisms, and the efficacy of combination antiviral regimens.
• Herpesvirus Studies: In vitro assays employing cidofovir help characterize herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus (VZV) polymerase fidelity and inhibitor binding.
• Adenovirus and Poxvirus Models: Given its broad-spectrum activity, cidofovir is employed in preclinical studies evaluating treatments for adenoviral disease in immunocompromised hosts and for orthopoxvirus infections including vaccinia and variola surrogate models.
• Antiviral Drug Resistance Studies: Cidofovir serves as a reference compound in phenotypic resistance assays, allowing researchers to profile polymerase mutations that reduce susceptibility to nucleotide analogues.
• Prodrug Development: Lipid conjugate prodrugs of cidofovir (e.g., brincidofovir) are an active area of investigation; the parent compound serves as the essential synthetic and biological benchmark.

Researchers should note that cidofovir has nephrotoxic potential in vivo; in cell-based assays, appropriate concentration ranges and cytotoxicity controls are essential experimental considerations.

Physicochemical Properties & Handling

Solubility: Cidofovir is freely soluble in water and in dilute aqueous base. It has limited solubility in most organic solvents. Stock solutions are typically prepared in sterile water or PBS at concentrations up to 10 mg/mL; warming and brief vortexing may be required for complete dissolution.

Stability: Prepared aqueous stock solutions should be aliquoted and stored at −20 °C to minimize freeze-thaw degradation. Repeated freeze-thaw cycles are not recommended. The solid form should be stored at room temperature or as directed, protected from light and moisture.

pH Sensitivity: Cidofovir is most stable at neutral to slightly alkaline pH. Prolonged exposure to strongly acidic or basic conditions may lead to hydrolysis of the phosphonate ester linkage.

Safety Considerations: Cidofovir is classified as potentially teratogenic and carcinogenic based on animal study data. Researchers must handle this compound using appropriate personal protective equipment (PPE), including nitrile gloves, lab coat, and eye protection. All manipulations should be performed in a well-ventilated area or chemical fume hood. Waste should be disposed of in accordance with institutional and local regulations governing cytotoxic compounds.

Purity: Aladdin Scientific's cidofovir (SKU: C126447) is supplied at research-grade purity; refer to the certificate of analysis (CoA) for lot-specific purity data confirmed by HPLC.

Experimental Protocols & Concentration Guidelines

The following general guidelines are based on published antiviral research practice. Researchers should optimize conditions for their specific cell lines, viral strains, and assay formats.

In Vitro Antiviral Assays: For plaque reduction assays or cytopathic effect (CPE) inhibition assays against CMV or HSV, cidofovir is commonly tested across a concentration range of 0.1–100 µM. EC₅₀ values reported in the literature for cidofovir against CMV laboratory strains typically fall in the low micromolar range, though values vary by strain and assay conditions. Always include a no-drug virus control and a cell-only toxicity control.

Cytotoxicity Assessment: Prior to antiviral assays, determine the 50% cytotoxic concentration (CC₅₀) using an appropriate cell viability assay (e.g., MTS, MTT, or CellTiter-Glo) in the target cell line. The selectivity index (SI = CC₅₀ / EC₅₀) should be calculated and reported.

Stock Solution Preparation:

1. Dissolve cidofovir powder in sterile, endotoxin-free water to a concentration of 10 mg/mL (approximately 35.8 mM).
2. Sterilize by filtration through a 0.22 µm membrane filter.
3. Aliquot into single-use volumes, snap-freeze in liquid nitrogen or dry ice/ethanol, and store at −20 °C.

In Vivo Mouse Models: Reported intraperitoneal dosing regimens vary widely depending on the virus model and study objective. Researchers should consult primary literature and institutional animal care guidelines when designing in vivo experiments. Probenecid co-administration is commonly employed in clinical settings to reduce nephrotoxicity; its use in animal studies should be evaluated per experimental design.

Regulatory Status & Procurement Notes

Regulatory Background: Cidofovir (brand name Vistide®) received regulatory approval from the U.S. Food and Drug Administration (FDA) in 1996 for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It is supplied by Aladdin Scientific exclusively as a research reagent and is not intended for direct clinical or therapeutic use.

Research Use Only: The cidofovir supplied under SKU C126447 is intended solely for in vitro research and laboratory applications. It is not suitable for human or veterinary use, and it must not be used as a drug, food additive, or household chemical.

Export Controls: Cidofovir may be subject to export control regulations in certain jurisdictions due to its potential dual-use in biodefense research (particularly poxvirus countermeasures). Purchasers are responsible for compliance with all applicable local, national, and international regulations.

Ordering Information: Cidofovir is available from Aladdin Scientific under SKU C126447. Please refer to the current catalog or contact our technical support team for available pack sizes, pricing, and current stock status. A certificate of analysis (CoA) and safety data sheet (SDS) are available upon request or via the product page.